Schwab Intermediate-Term U.S. Treasury ETF (SCHR) Stake Lowered by SVA Plumb Wealth Management LLC

Share on StockTwits

SVA Plumb Wealth Management LLC decreased its holdings in shares of Schwab Intermediate-Term U.S. Treasury ETF (NYSEARCA:SCHR) by 58.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 25,844 shares of the company’s stock after selling 36,718 shares during the quarter. SVA Plumb Wealth Management LLC’s holdings in Schwab Intermediate-Term U.S. Treasury ETF were worth $1,390,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of SCHR. Madison Investment Holdings Inc. boosted its stake in Schwab Intermediate-Term U.S. Treasury ETF by 29.1% in the fourth quarter. Madison Investment Holdings Inc. now owns 2,256,616 shares of the company’s stock worth $119,488,000 after buying an additional 508,763 shares in the last quarter. IndexIQ Advisors LLC boosted its stake in Schwab Intermediate-Term U.S. Treasury ETF by 212.0% in the fourth quarter. IndexIQ Advisors LLC now owns 554,193 shares of the company’s stock worth $29,345,000 after buying an additional 376,552 shares in the last quarter. Tradewinds Capital Management LLC purchased a new stake in Schwab Intermediate-Term U.S. Treasury ETF in the first quarter worth approximately $28,759,000. Financial Engines Advisors L.L.C. boosted its stake in Schwab Intermediate-Term U.S. Treasury ETF by 1,394.6% in the fourth quarter. Financial Engines Advisors L.L.C. now owns 381,429 shares of the company’s stock worth $18,282,000 after buying an additional 355,908 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in Schwab Intermediate-Term U.S. Treasury ETF by 1.6% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 317,866 shares of the company’s stock worth $16,965,000 after buying an additional 5,010 shares in the last quarter.

Shares of SCHR opened at $53.89 on Thursday. Schwab Intermediate-Term U.S. Treasury ETF has a 1 year low of $51.31 and a 1 year high of $53.96.

The company also recently announced a monthly dividend, which was paid on Tuesday, May 7th. Shareholders of record on Thursday, May 2nd were paid a $0.1075 dividend. This represents a $1.29 annualized dividend and a yield of 2.39%. The ex-dividend date was Wednesday, May 1st.

WARNING: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4343112/schwab-intermediate-term-u-s-treasury-etf-schr-stake-lowered-by-sva-plumb-wealth-management-llc.html.

Featured Story: The benefits and drawbacks of dollar cost averaging

Want to see what other hedge funds are holding SCHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Schwab Intermediate-Term U.S. Treasury ETF (NYSEARCA:SCHR).

Institutional Ownership by Quarter for Schwab Intermediate-Term U.S. Treasury ETF (NYSEARCA:SCHR)

Receive News & Ratings for Schwab Intermediate-Term U.S. Treasury ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Schwab Intermediate-Term U.S. Treasury ETF and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Atara Biotherapeutics  Now Covered by Stifel Nicolaus
Atara Biotherapeutics Now Covered by Stifel Nicolaus
Critical Contrast: MFC Bancorp  and Bancolombia
Critical Contrast: MFC Bancorp and Bancolombia
Paragon Banking Group’s  Hold Rating Reiterated at Numis Securities
Paragon Banking Group’s Hold Rating Reiterated at Numis Securities
Short Interest in Moleculin Biotech Inc  Grows By 327.4%
Short Interest in Moleculin Biotech Inc Grows By 327.4%
OrganiGram  Sets New 52-Week High at $11.30
OrganiGram Sets New 52-Week High at $11.30
Weekly Analysts’ Ratings Changes for Seres Therapeutics
Weekly Analysts’ Ratings Changes for Seres Therapeutics


© 2006-2019 Ticker Report